Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 4Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 3Hematologic Neoplasms 3Myeloproliferative Disorders 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Primary Myelofibrosis 1Plasmacytoma 1Neoplasms 1Myelodysplastic Syndromes 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Lymphatic Diseases 1Leukemia, Plasma Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Leukemia 1

Interventions

Cyclophosphamide 85fludarabine phosphate 84Peripheral Blood Stem Cell Transplantation 70Mycophenolic Acid 58Tacrolimus 57Whole-Body Irradiation 55Busulfan 54Antilymphocyte Serum 47Cyclosporine 45Methotrexate 38fludarabine 37Filgrastim 37Melphalan 32Radiotherapy 27Cytarabine 27Etoposide 21Methylprednisolone 20Cord Blood Stem Cell Transplantation 18Azacitidine 18Sirolimus 15Granulocyte Colony-Stimulating Factor 15Flow Cytometry 14Cyclosporins 14thymoglobulin 13Specimen Handling 13Alemtuzumab 13Biopsy 12venetoclax 10Thiotepa 10Decitabine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × pomalidomide × Other hematologic neoplasm × Clear all
NCT04802161 2025-12-19

Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

National Cancer Institute (NCI)

Phase 2 Active not recruiting
50 enrolled 12 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02029950 2020-10-14

Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

National Cancer Institute (NCI)

Phase 1 Completed
50 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡